JANUX THERAPEUTICS INC (JANX) Stock Price & Overview
NASDAQ:JANX • US47103J1051
Current stock price
The current stock price of JANX is 15.07 USD. Today JANX is down by -0.79%. In the past month the price increased by 10.07%. In the past year, price decreased by -51.08%.
JANX Key Statistics
- Market Cap
- 916.708M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -1.83
- Dividend Yield
- N/A
JANX Stock Performance
JANX Stock Chart
JANX Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to JANX. When comparing the yearly performance of all stocks, JANX is a bad performer in the overall market: 87.41% of all stocks are doing better.
JANX Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to JANX. No worries on liquidiy or solvency for JANX as it has an excellent financial health rating, but there are worries on the profitability.
JANX Earnings
JANX Forecast & Estimates
26 analysts have analysed JANX and the average price target is 54.57 USD. This implies a price increase of 262.11% is expected in the next year compared to the current price of 15.07.
For the next year, analysts expect an EPS growth of -41.9% and a revenue growth -10.15% for JANX
JANX Groups
Sector & Classification
JANX Financial Highlights
Over the last trailing twelve months JANX reported a non-GAAP Earnings per Share(EPS) of -1.83. The EPS decreased by -42.97% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -11.34% | ||
| ROE | -11.88% | ||
| Debt/Equity | 0 |
JANX Ownership
JANX Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.4 | 355.432B | ||
| AMGN | AMGEN INC | 15.18 | 188.147B | ||
| GILD | GILEAD SCIENCES INC | 14.74 | 165.877B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.15 | 110.672B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.95 | 80.984B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 44.61 | 41.869B | ||
| INSM | INSMED INC | N/A | 31.046B | ||
| NTRA | NATERA INC | N/A | 28.508B | ||
| BIIB | BIOGEN INC | 11.41 | 27.573B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 26.65B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.35 | 25.108B | ||
| MRNA | MODERNA INC | N/A | 20.96B | ||
| INCY | INCYTE CORP | 12.29 | 19B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About JANX
Company Profile
Janux Therapeutics, Inc. operates a preclinical stage biopharmaceutical company which engages in developing therapeutics based on the Tumor Activated T Cell Engager platform technology. The company is headquartered in San Diego, California and currently employs 109 full-time employees. The company went IPO on 2021-06-11. The company has developed two bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain. Its clinical candidates include JANX007 and JANX008. JANX007 is a prostate-specific membrane antigen (PSMA-TRACTr) designed to target PSMA, a protein expressed in prostate cancer tumors and the vasculature of other tumors. JANX008 is an epidermal growth factor receptor (EGFR-TRACTr), being studied for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.
Company Info
IPO: 2021-06-11
JANUX THERAPEUTICS INC
10955 Vista Sorrento Parkway, Suite 200
San Diego CALIFORNIA US
CEO: David Campbell
Employees: 109
Phone: 13026587581
JANUX THERAPEUTICS INC / JANX FAQ
What does JANX do?
Janux Therapeutics, Inc. operates a preclinical stage biopharmaceutical company which engages in developing therapeutics based on the Tumor Activated T Cell Engager platform technology. The company is headquartered in San Diego, California and currently employs 109 full-time employees. The company went IPO on 2021-06-11. The company has developed two bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain. Its clinical candidates include JANX007 and JANX008. JANX007 is a prostate-specific membrane antigen (PSMA-TRACTr) designed to target PSMA, a protein expressed in prostate cancer tumors and the vasculature of other tumors. JANX008 is an epidermal growth factor receptor (EGFR-TRACTr), being studied for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.
Can you provide the latest stock price for JANUX THERAPEUTICS INC?
The current stock price of JANX is 15.07 USD. The price decreased by -0.79% in the last trading session.
Does JANX stock pay dividends?
JANX does not pay a dividend.
How is the ChartMill rating for JANUX THERAPEUTICS INC?
JANX has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
Which stock exchange lists JANX stock?
JANX stock is listed on the Nasdaq exchange.
What is the market capitalization of JANX stock?
JANUX THERAPEUTICS INC (JANX) has a market capitalization of 916.71M USD. This makes JANX a Small Cap stock.